BVS - Bioventus Inc. Stock Price, Fair Value and News

$10.67+0.15 (+1.43%)

Delayed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

BVS Price Action

Last 7 days

-3.3%

Last 30 days

-6.5%

Last 90 days

-10.0%

Trailing 12 Months

107.2%

BVS RSI Chart

BVS Valuation

Market Cap

685.4M

Price/Earnings (Trailing)

-17.36

Price/Sales (Trailing)

1.23

EV/EBITDA

-19.83

Price/Free Cashflow

23.6

BVS Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

BVS Fundamentals

BVS Revenue

Revenue (TTM)

555.1M

Rev. Growth (Yr)

15.04%

Rev. Growth (Qtr)

-8.1%

BVS Earnings

Earnings (TTM)

-39.5M

Earnings Growth (Yr)

33.94%

Earnings Growth (Qtr)

79.89%

BVS Profitability

EBT Margin

-10.41%

Return on Equity

-26.54%

Return on Assets

-5.13%

Free Cashflow Yield

4.24%

BVS Investor Care

Shares Dilution (1Y)

2.78%

Diluted EPS (TTM)

-0.59

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	522.7M	536.9M	555.1M	0
2023	513.9M	510.6M	502.8M	512.3M
2022	466.4M	496.9M	516.7M	512.1M
2021	324.3M	376.1M	399.1M	430.9M
2020	335.4M	330.7M	325.9M	321.2M
2019	0	0	0	340.1M
2018	0	0	0	319.2M

Get all data in R, Python etc through our Historical Stock Data APIs

About Bioventus Inc.

Bioventus Inc., a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical joint pain injection therapies, as well as peripheral nerve stimulation products. Its surgical solutions comprise bone graft substitutes to fuse and grow bones, enhance results following spinal and other orthopedic surgeries; and ultrasonic medical devices used for precise bone sculpting, removing tumors, and tissue debridement. The company's restorative therapies include a bone healing system; skin allografts; and products that are used to support healing of wounds, as well as devices designed to help patients regain leg or hand function due to stroke, multiple sclerosis, or other central nervous system disorders. It serves physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine, and neurosurgery in the physician's office or clinic, ambulatory surgical centers, or in the hospital setting. The company was founded in 2011 and is headquartered in Durham, North Carolina.

CEO	Mr. Anthony P. Bihl III
WEBSITE	bioventus.com
SECTOR	Healthcare
INDUSTRY	Medical Devices
EMPLOYEES	950

Bioventus Inc. Frequently Asked Questions

What is the ticker symbol for Bioventus Inc.? What does BVS stand for in stocks?

BVS is the stock ticker symbol of Bioventus Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Bioventus Inc. (BVS)?

As of Fri Dec 20 2024, market cap of Bioventus Inc. is 685.39 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of BVS stock?

You can check BVS's fair value in chart for subscribers.

Is Bioventus Inc. a good stock to buy?

The fair value guage provides a quick view whether BVS is over valued or under valued. Whether Bioventus Inc. is cheap or expensive depends on the assumptions which impact Bioventus Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for BVS.

What is Bioventus Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Dec 20 2024, BVS's PE ratio (Price to Earnings) is -17.36 and Price to Sales (PS) ratio is 1.23. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. BVS PE ratio will change depending on the future growth rate expectations of investors.